CareDx

CareDx, Inc. operates as a transplant diagnostics company, which discovers, develops and commercializes diagnostic solutions. Its products include AlloMap, AlloSure and Laboratory products. The company was founded on December 21, 1998 and is headquartered in Brisbane, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

CareDx reports solid Q4 earnings, eyes profitable growth in 2023

CareDx delivered strong financial results, focusing on profitable growth and strategic initiatives to drive revenue and market leadership.
While facing challenges such as fluctuating transplant volumes and market risks, the company is actively pursuing opportunities for expansion and innovation.
Overall, CareDx's performance, strengths, and proactive approach to challenges and opportunities position it for continued success and growth in the coming year.

CareDx reports Q1 2023 operational success amidst billing challenges

CareDx faced billing challenges impacting Medicare reimbursement but maintained strong operational performance and financial profile. The company is focused on mitigating financial impacts, managing cash flow, and pursuing growth opportunities through new modalities and publications.

CareDx reports Q2 revenue, faces Billing Article impact challenges

CareDx navigated challenges in Q2 2023 with a focus on financial strength, operational excellence, and strategic growth initiatives, despite a decline in Testing Services revenue.
The company's strong cash position, successful strategic executions, and pipeline catalysts position it well for future growth and expansion across Medicare and commercial plans.
While facing uncertainties and cost-saving initiatives, CareDx remains committed to achieving adjusted EBITDA positivity and overcoming challenges to drive long-term value for stakeholders.

CareDx reports solid Q3 earnings, eyes growth through expanded coverage

CareDx's Q3 2023 performance reflects revenue growth and improved EBITDA, driven by key business segments.
While facing challenges like CEO transition and payer coverage, the company is well-positioned for growth opportunities.
Strategic initiatives focusing on expanding coverage and driving testing volume growth indicate a positive outlook for CareDx.

CareDx surpasses revenue targets, eyes growth in transplant services

CareDx delivered strong financial performance in 2023, exceeding revenue guidance and focusing on strategic growth initiatives for 2024.
Despite facing challenges such as ongoing patent litigation and CEO search, the company is well-positioned to drive profitability and expand its offerings.
Opportunities for revenue growth exist in digital solutions, lab products, and transplant services, with potential catalysts for growth on the horizon.
CareDx's advocacy efforts and commercial expansions underscore its commitment to innovation and patient access in the transplant space.

CareDx reports robust Q1 earnings, raises guidance amidst market expansion

CareDx delivered strong financial results, showcasing growth across key business segments and improving EBITDA performance.
The company's focus on innovation, market expansion, and cost management positions it well for future growth and profitability.
With a solid cash position, positive clinical data, and expanded market coverage, CareDx is poised for continued success in the healthcare sector.

CareDx reports strong Q2 earnings, raises FY guidance confidently

CareDx delivered robust financial results in Q2 2024, driven by revenue growth, improved adjusted EBITDA, and successful validation studies for its diagnostic solutions.
The company's raised revenue guidance, expanding payer coverage, and planned Investor Day reflect a positive outlook and strategic focus on long-term growth.
While facing challenges in a competitive landscape, CareDx remains well-positioned to leverage opportunities in transplant diagnostics and healthcare innovation.
Investors can be optimistic about CareDx's performance, innovation pipeline, and strategic initiatives aimed at sustainable growth and market leadership.

CareDx reports robust Q3 earnings, targets $500M revenue by 2027

CareDx delivered strong financial performance in Q3 2024, driven by revenue growth, improved margins, and operational efficiencies.
The company's strategic initiatives to engage transplant centers and expand payer coverage have yielded positive results.
While facing challenges in operational execution and sustaining growth, CareDx remains optimistic about its future prospects and revenue targets.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced its second annual digital health user conference, the Management Expert Exchange in Transplantation (MEET) Conference, taking place August 27-29 in Dallas, Texas. Transplant administrators, quality managers, transplant clinicians,.

CareDx Hosts Second Annual MEET Digital Health User Conference to Showcase Latest Innovations to Enhance Transplant Patient Care

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today commented on the issuance of proposed changes to the Local Coverage Determination (LCD) MolDX Molecular Testing for Solid Organ Allograft Rejection that covers AlloSure®, AlloMap® and HeartCare. CareDx is pleased that MolDX is p.

CareDx Comments on Issuance of Proposed LCD for Molecular Testing for Solid Allograft Rejection

CareDx, Inc. (NASDAQ:CDNA ) Q2 2023 Earnings Conference Call August 8, 2023 4:30 PM ET Company Participants Greg Chodaczek - Gilmartin Group, IR Reg Seeto - President, CEO Abhishek Jain - CFO Robert Woodward - SVP, R&D Conference Call Participants Andrew Cooper - Raymond James Brandon Couillard - Jefferies Alex Nowak - Craig-Hallum Capital Mason Carrico - Stephens Inc. Operator Greetings, and welcome to the CareDx, Incorporated Second Quarter 2023 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded, Tuesday, August 8, 2023.

CareDx, Inc. (CDNA) Q2 2023 Earnings Call Transcript

CareDx (CDNA) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to loss of $0.13 per share a year ago.

CareDx (CDNA) Reports Q2 Loss, Tops Revenue Estimates

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today reported financial results for the second quarter ended June 30, 2023. Second Quarter 2023 Highlights and Other Recent Updates CareDx received the industry's first and only multimodal MolDX approval in transplant with HeartCare for Medicare.

CareDx Reports Second Quarter 2023 Results

Natera

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the United States District Court for the District of Delaware (the “District Court”) issued an injunction prohibiting Natera (Nasdaq: NTRA) from continuing to falsely advertise and overstate the scientific performance of its.

CareDx Announces District Court Judge Bars Natera from Falsely Advertising and Overstating the Scientific Performance of its Prospera Transplant Test

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the second quarter 2023 after market close on Tuesday, August 8th, 2023. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Tim.

CareDx to Report Second Quarter 2023 Financial Results

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced Medicare coverage for HeartCare, a multimodality testing service that includes both AlloMap® Heart and AlloSure® Heart, in a given patient encounter, for heart transplant surveillance. Coverage is effective April 1, 20.

CareDx's HeartCare Multimodality Service Receives Medicare Coverage for Heart Transplant Surveillance

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced the acquisition of MediGO, Inc. in a strategic move to expand its digital health portfolio to serve the organ procurement organization (OPO) market while also bolstering its pre-transplant offerings aimed at shortening.

CareDx Acquires MediGO, an Organ Transplant Supply Chain and Logistics Company

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the United States District Court for the District of Delaware (the “District Court”) decision upheld and reaffirmed the March 2022 jury verdict finding that Natera (Nasdaq: NTRA) violated the Lanham Act by falsely advertising.

CareDx Applauds District Court Decision to Uphold Jury Verdict that Natera Falsely Advertised its Prospera Transplant Test

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that CareDx's AlloSure® Lung donor-derived cell-free DNA (dd-cfDNA) molecular testing service has received Medicare coverage. The MolDX technology assessment program has determined that AlloSure Lung will be covered under the exis.

CareDx's AlloSure Lung dd-cfDNA Testing Service Receives Medicare Coverage for Lung Transplant Rejection Monitoring

CareDx (CDNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

CareDx (CDNA) Soars 20.6%: Is Further Upside Left in the Stock?

CareDx specializes in diagnostic testing for transplant patients. The company's revenue declined 3% year over year in the first quarter.

Why Shares of CareDx Are Jumping Friday

Adaptive Biotechnologies

COMPASS Pathways

Genius Sports

908 Devices

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

5 of Cathie Wood's Sizzling ARK Investment Stocks Are Buy Rated and Trading Under $10

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced a leading presence at the 2023 American Transplant Congress (ATC) with 65 scientific presentations. CareDx will also be hosting a satellite symposium1 and sponsoring the Women's Networking Event. The ATC meeting takes place June 3.

CareDx Demonstrates Innovation Leadership at 2023 Transplant Congress

ACADIA Pharma

Agios Pharmaceuticals

Amgen

ARK Genomic Revolution Multi-Sector ETF

VanEck Vectors Biotech ETF

BioMarin Pharmaceutical

Exact Sciences

Exelixis

First Trust NYSE Arca Biotechnology Index Fund

FibroGen

Gilead Sciences

iShares Nasdaq Biotechnology ETF

Ionis Pharma

IQVIA Hlds

Madrigal Pharmaceuticals

Moderna

Pacific Biosciences of California

Regeneron Pharmaceuticals

Seagen

Teladoc

TG Therapeutics

Vertex Pharmaceuticals

SPDR S&P Biotech ETF

Here are the five best biotech ETFs to invest in right now.

Investing in Biotech ETFs

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that it will showcase its digital health portfolio and host a symposium which addresses barriers in access to transplantation at the 31st Annual UNOS Transplant Management Forum (TMF) taking place May 16-18 in Denver,.

CareDx Showcases Digital Health Portfolio at 31st Annual UNOS Transplant Management Forum

CareDx, Inc. (NASDAQ:CDNA ) Q1 2023 Earnings Conference Call May 10, 2023 4:30 PM ET Company Participants Greg Chodaczek - Gilmartin Group, IR Reg Seeto - President, CEO Abhishek Jain - CFO Robert Woodward - SVP, R&D Conference Call Participants Matt Sykes - Goldman Sachs Andrew Cooper - Raymond James Brandon Couillard - Jefferies Mark Massaro - BTIG Alex Nowak - Craig-Hallum Capital Group Mason Carrico - Stephens Inc. Operator Greetings. And welcome to the CareDx, Inc. First Quarter 2023 Earnings Conference Call.

CareDx, Inc. (CDNA) Q1 2023 Earnings Call Transcript

CareDx (CDNA) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to loss of $0.13 per share a year ago.

CareDx (CDNA) Reports Q1 Loss, Lags Revenue Estimates

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today reported financial results for the first quarter ended March 31, 2023. First Quarter 2023 Highlights Delivered record number of patient test results for AlloMap® and AlloSure® of approximately 49,900 tests, growing year-over-year by 17%, an.

CareDx Reports First Quarter 2023 Results

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the first quarter 2023 after market close on Wednesday, May 10, 2023. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

CareDx to Report First Quarter 2023 Financial Results

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that it will showcase the latest developments across its AlloSeq®* portfolio during the 36th European Immunogenetics and Histocompatibility Conference taking place April 26-29 in Nantes, France. “We look forward to par.

CareDx Showcases Latest Advances Across AlloSeq Lab Products Portfolio at the 36th European Immunogenetics and Histocompatibility Conference

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc.

CareDx Showcases Leadership with Over 55 Oral Presentations and Posters at the 43rd Annual Meeting & Scientific Sessions of the International Society for Heart and Lung Transplantation

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the National Kidney Foundation honored CareDx with a corporate citizenship award during its 41st Annual Kidney Ball held on March 31, 2023, in Washington, D.C.

National Kidney Foundation Honors CareDx with Corporate Citizenship Award for its Commitment to the Transplant Community

Miromatrix Medical Inc

BRISBANE, Calif. & EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) and Miromatrix Medical Inc. (“Miromatrix”) (Nasdaq: MIRO) – today announced an exclusive partnership aimed at advancing the next wave of innovation using fully transplantable human bioengineered organs.

News for CareDx Stock (CDNA)